There’s an urgent need to improve and extend the lives of patients with rare neurodegenerative diseases, and the FDA is hoping a new five-year action plan, which has a specific detailed blueprint for amyotrophic lateral sclerosis (ALS), can help accelerate new medicines.
The broader plan will establish a new FDA Rare Neurodegenerative Disease Task Force, a public-private partnership focused on speeding up the creation of disease-specific science strategies and leveraging ongoing FDA regulatory science efforts to boost scientific advances.